Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7844700 | 0.83 | CYP19A1 (0.49) | LTA4HNPC1TAAR1MAPTNPSR1 | |
| SCHEMBL28567271 | 0.82 | NPC1 (0.59) | LTA4HNPC1RAB9ATAAR1KDM4E | |
| SCHEMBL3236567 | 0.80 | HPGD (0.53) | NPC1RAB9ATAAR1KDM4ENPSR1 | |
| SCHEMBL6096446 | 0.79 | MEN1 (0.49) | LTA4HNPC1RAB9AL3MBTL1POLB | |
| SCHEMBL45228 | 0.77 | LMNA (0.50) | NPC1RAB9ATAAR1KDM4EL3MBTL1 | |
| SCHEMBL2096666 | 0.76 | SRD5A2 (0.59) | LTA4HTAAR1KDM4EIDO1SRD5A2 | |
| SCHEMBL11660485 | 0.76 | TAAR1 (0.42) | LTA4HTAAR1L3MBTL1PTGS1PTGS2 | |
| SCHEMBL10953000 | 0.76 | HPGD (0.46) | LTA4HTAAR1POLBPTGS1PTGS2 | |
| SCHEMBL20738474 | 0.76 | MEN1 (0.61) | LTA4HNPC1RAB9ATAAR1MAPT | |
| SCHEMBL10525378 | 0.76 | L3MBTL1 (0.55) | LTA4HTAAR1L3MBTL1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119096372-A | Photovoltaic device and method of manufacture | 第一阳光公司 | 2024-12-06 | — | — | CN | claimed |
| CN-116918029-A | selective thermal atomic layer deposition | 弗萨姆材料美国有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| CN-116761906-A | Selective plasma enhanced atomic layer deposition | 弗萨姆材料美国有限责任公司 | 2023-09-15 | — | — | CN | claimed |
| CN-110192294-B | Lithium electrode and lithium secondary battery comprising same | 株式会社LG新能源 | 2022-09-20 | — | — | CN | claimed |
| CN-111033864-B | Electrolyte for lithium metal battery and lithium metal battery comprising same | 株式会社LG新能源 | 2022-08-12 | — | — | CN | claimed |
| CN-120129685-A | Heterobicyclic compounds as EP4 receptor antagonists | 深圳市原力生命科学有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-116918029-A | selective thermal atomic layer deposition | 弗萨姆材料美国有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116761906-A | Selective plasma enhanced atomic layer deposition | 弗萨姆材料美国有限责任公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-111763164-B | Preparation method and application of ortho-carbonyl amino substituted benzene derivatives | 中国医学科学院药物研究所 | 2023-03-10 | — | — | CN | disclosed |
| CN-110192294-B | Lithium electrode and lithium secondary battery comprising same | 株式会社LG新能源 | 2022-09-20 | — | — | CN | disclosed |
| CN-111033864-B | Electrolyte for lithium metal battery and lithium metal battery comprising same | 株式会社LG新能源 | 2022-08-12 | — | — | CN | disclosed |
| CN-107848283-B | Anisotropic conductive film and display device using the same | 国都化学(株) | 2021-04-13 | — | — | CN | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
| EP-1077927-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058495-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1999-11-18 | — | — | WO | disclosed |
| EP-0912183-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0912183-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997039753-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| US-4837316-A | ANTIULCER AGENTS | FUJIREBIO KABUSHIKI KAISHA (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0214823-A2 | Alkylamide derivatives with H2-receptor antagonistic and cytoprotective action | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | LTA4H 2200/4885NPC1 2639/4885RAB9A 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.